We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Theranos Shuts Down Blood-Testing Facilities, Lets Go of 340 Workers

Theranos Shuts Down Blood-Testing Facilities, Lets Go of 340 Workers

November 4, 2016

Theranos has announced that it will close its blood-testing facilities.

In an open letter to stakeholders, CEO Elizabeth Holmes said the company will close its clinical labs and Theranos Wellness Centers, which will impact about 340 employees in Arizona, California, and Pennsylvania – roughly one-fourth of the company’s workforce.

“After many months spent assessing our strengths and addressing our weaknesses, we have moved to structure our company around the model best aligned with our core values and mission,” Holmes said, adding that the company will be focusing on its new miniLab platform.

“Our ultimate goal is to commercialize miniaturized, automated laboratories capable of small-volume sample testing, with an emphasis on vulnerable patient populations, including oncology, pediatrics, and intensive care,” she said.

Holmes said the company has a new executive team working toward “obtaining FDA clearances, building commercial partnerships, and pursuing publications in scientific journals.” Theranos unveiled its miniLab platform in August at the American Association for Clinical Chemistry meeting.

The miniLab technology miniaturizes analytical testing equipment across different testing methods, including hematology, immunology, clinical chemistry, immunochemistry, and nucleic acid amplification.

Holmes discussed the company’s Zika nucleic acid amplification-based assay for which the company had hoped to secure FDA emergency use authorization. The firm later withdrew its request for emergency use authorization following an FDA inspection that found irregularities in protocols for trials conducted in the Dominican Republic.

CMS Sanctions

CMS sanctions prohibit Holmes from owning or operating a lab. The company has announced plans to appeal the CMS sanctions imposed on the company’s Newark, Calif., lab following multiple quality control failures at the blood testing company.

CMS also revoked the company’s Clinical Laboratory Improvement Amendments certificate, imposed monetary penalties, suspended the lab’s approval to be reimbursed by Medicare and Medicaid and said it would oversee a directed correction plan for the beleaguered company.

Following a CMS noncompliance determination in March, Theranos rescinded test results from the past two years for its Edison blood-testing diagnostics. The company issued corrected test results to doctors and patients and also voided results for some tests. In addition to filing a plan of correction, the company suspended further testing.

The Department of Justice’s interim final rule virtually doubles penalities for those that violate the False Claims Act. How can you avoid liability under the FCA? FDAnews’s webinar CD on: False Claims Act Liability for Regulatory Noncompliance: An Update for Drug and Device Manufacturers gives insider detail to do just that.

View today's stories

Medical Devices Inspections and Audits

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

  • UKflag.jpg

    UK Study Says Single Shot of Pfizer/BioNTech Vaccine Significantly Lessened Asymptomatic Infections

  • emergency use authorization approved

    Eurofins Receives FDA Emergency Authorization for Over-the-Counter COVID-19 Test

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing